Continuous subcutaneous GHRH(1-29)NH2 promotes growth over 1 year in short, slowly growing children.

Brain CE, Hindmarsh PC, Brook CG

Clinical endocrinology1 Feb 1990Cited by 11 (Europe PMC)

PMID2140733DOI10.1111/j.1365-2265.1990.tb00851.xPepBankPUB-02140733

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In children treated with GHRH(1-29)NH2, growth rates returned to pretreatment levels after treatment stopped.
In plain wordsIn short children, growth speed went back to the level before treatment once the GHRH infusion stopped.
Peptide
Sermorelin
Outcome
DecreaseGrowth velocity after treatment stopped
Study
n = 8
Outcome group
Linear growth · Endocrine and hormones
Studied dose
60 ng/kg/min · subcutaneous infusion · up to 1 yearAs given in this study (human).
Source sentences
Summary
A return to pretreatment growth rates was seen after cessation of treatment in all children.
1 context sentence(design, population, supporting numbers)
Summary · context
We have treated eight pre-pubertal children with partial GH insufficiency with continuous subcutaneous infusions of GHRH(1-29)NH2 at a dose of 60 ng/kg/min for periods of up to 1 year.
Report a problemFND-0214073303
02HumanNon-randomized trialEfficacy outcome
In pre-pubertal children with partial GH insufficiency, 1 year of continuous subcutaneous GHRH(1-29)NH2 raised mean growth velocity from 4.6 to 7.0 cm/year (P = 0.04).
In plain wordsIn short children with partial growth hormone shortage, a year of continuous GHRH infusion raised growth speed, with no control group.
Peptide
Sermorelin
Outcome
IncreaseGrowth velocity after 1 year
Study
n = 5
Outcome group
Linear growth · Endocrine and hormones
Studied dose
60 ng/kg/min · subcutaneous infusion · 1 yearAs given in this study (human).
Measurements
Growth velocity
4.6 cm/year
before treatment
Growth velocity
7 cm/year
after 1 year
Source sentences
Summary
In five children treated for 1 year, mean growth velocity increased from 4.6 cm/year (range 4.4-5.2) to 7.0 cm/year (5.7-8.7) (P = 0.04).
1 context sentence(design, population, supporting numbers)
Summary · context
We have treated eight pre-pubertal children with partial GH insufficiency with continuous subcutaneous infusions of GHRH(1-29)NH2 at a dose of 60 ng/kg/min for periods of up to 1 year.
Report a problemFND-0214073301
03HumanNon-randomized trialEfficacy outcome
In three children treated for 3-6 months, GHRH(1-29)NH2 gave similar increases in height velocity.
In plain wordsIn three short children treated for 3 to 6 months, growth speed rose in a similar way, with no control group.
Peptide
Sermorelin
Outcome
IncreaseGrowth velocity after 3-6 months
Study
n = 3
Outcome group
Linear growth · Endocrine and hormones
Studied dose
60 ng/kg/min · subcutaneous infusion · 3-6 monthsAs given in this study (human).
Source sentences
Summary
Three children treated for 3-6 months showed similar height velocity increases.
1 context sentence(design, population, supporting numbers)
Summary · context
We have treated eight pre-pubertal children with partial GH insufficiency with continuous subcutaneous infusions of GHRH(1-29)NH2 at a dose of 60 ng/kg/min for periods of up to 1 year.
Report a problemFND-0214073302
04HumanNon-randomized trialEfficacy outcome
In children with partial GH insufficiency, continuous GHRH(1-29)NH2 sustained augmented pulsatile GH secretion without evidence of desensitization.
In plain wordsIn short children, continuous GHRH infusion kept growth hormone pulses raised over time, with no sign that the response faded.
Peptide
Sermorelin
Outcome
Increase24-hour pulsatile GH secretion
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
60 ng/kg/min · subcutaneous infusion · up to 1 yearAs given in this study (human).
Source sentences
Summary
Twenty-four-hour GH profiles performed at intervals of 3 months showed sustained augmentation of pulsatile GH secretion without evidence of desensitization.
1 context sentence(design, population, supporting numbers)
Summary · context
We have treated eight pre-pubertal children with partial GH insufficiency with continuous subcutaneous infusions of GHRH(1-29)NH2 at a dose of 60 ng/kg/min for periods of up to 1 year.
Report a problemFND-0214073304
05HumanNon-randomized trialEfficacy outcome
In children treated with continuous GHRH, the pituitary GH response to a supramaximal GHRH bolus remained constant during treatment.
In plain wordsIn short children, the growth hormone response to a large GHRH dose stayed the same during the infusion.
Peptide
Sermorelin
Outcome
No significant changeGH response to supramaximal GHRH bolus
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
60 ng/kg/min · subcutaneous infusion · up to 1 yearAs given in this study (human).
Source sentences
Summary
The ability of the pituitary to respond to a supramaximal bolus of GHRH remained constant during the treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
We have treated eight pre-pubertal children with partial GH insufficiency with continuous subcutaneous infusions of GHRH(1-29)NH2 at a dose of 60 ng/kg/min for periods of up to 1 year.
Report a problemFND-0214073305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 10:21 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.